Eskelund CW, Albertsson-Lindblad A, Kolstad A, Laurell A, Räty R, Pedersen LB, Geisler CH, Jerkeman M, Grønbæk K. Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma. Haematologica [Internet]. 2018Oct.31 [cited 2026Nov.12];103(11):e541-e543. Available from: https://haematologica.org/article/view/8682